Pathological Complete Response Predicts Outcomes in Hormone Receptor-Positive, HER2-Negative Breast Cancer After Neoadjuvant Chemotherapy

A multicenter cohort study investigated the prognostic significance of achieving a pathological complete response (pCR) in patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer who received neoadjuvant chemotherapy. The research aimed to understand how this specific treatment outcome impacts long-term survival and recurrence rates within this patient subgroup. Neoadjuvant chemotherapy is administered before surgery to shrink tumors, making them easier to remove and potentially increasing the chances of a complete response. A pathological complete response is defined as the absence of invasive cancer in both the breast and the lymph nodes after treatment. The study analyzed data from multiple institutions to ensure a robust and generalizable conclusion. The findings are expected to inform treatment decisions and patient counseling regarding the benefits and implications of achieving pCR. This research contributes to the growing body of evidence on personalized medicine in breast cancer, highlighting the importance of treatment response assessment in tailoring future therapeutic strategies. The study's results will be crucial for oncologists in evaluating the effectiveness of current neoadjuvant regimens for HR+/HER2- breast cancer.